Volume | 2,119,014 |
|
|||||
News | - | ||||||
Day High | 4.2799 | Low High |
|||||
Day Low | 3.90 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aquestive Therapeutics Inc | AQST | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.25 | 3.90 | 4.2799 | 3.90 | 4.28 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,802 | 2,119,014 | $ 4.10 | $ 8,678,362 | - | 1.15 - 6.23 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:15:27 | 2 | $ 3.99 | USD |
Aquestive Therapeutics (AQST) Options Flow Summary
Aquestive Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
285.87M | 73.30M | - | 50.58M | -7.87M | -0.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aquestive Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AQST Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.94 | 4.54 | 3.82 | 4.29 | 2,814,842 | 0.06 | 1.52% |
1 Month | 4.13 | 4.54 | 3.72 | 4.17 | 2,719,204 | -0.13 | -3.15% |
3 Months | 2.40 | 6.23 | 2.3601 | 4.27 | 2,657,794 | 1.60 | 66.67% |
6 Months | 1.41 | 6.23 | 1.3664 | 3.89 | 1,514,663 | 2.59 | 183.69% |
1 Year | 1.40 | 6.23 | 1.15 | 3.43 | 977,619 | 2.60 | 185.71% |
3 Years | 4.09 | 6.40 | 0.618 | 2.97 | 686,506 | -0.09 | -2.20% |
5 Years | 6.15 | 10.00 | 0.618 | 4.03 | 693,462 | -2.15 | -34.96% |
Aquestive Therapeutics Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. |